Histological Diagnostics of Malignant Melanoma: State of the Art and Perspectives

A special issue of Dermatopathology (ISSN 2296-3529).

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 11218

Special Issue Editors


E-Mail Website
Guest Editor
Section of Pathology, Department of Emergency and Organ Transplantation (DETO), University of Bari Aldo Moro, 70124 Bari, Italy
Interests: malignant melanoma; non-melanoma skin cancer; skin tumours; gynecopathology; ovarian tumours; endometrial cancer; placenta

Special Issue Information

Dear Colleague,

Malignant melanoma continues to represent a diagnostic challenge for dermatology specialist histopathologists. The extreme variability in clinical pictures, together with its morphological and immunohistochemical heterogeneity, still make it the "great mimic" of human pathology today. In memory of Dr. Antonietta Cimmino, a fine dermatopathologist and student of Prof. G. De Benedictis, from the University of Bari "Aldo Moro", we are launching this Special Issue aimed at collecting original contributions regarding cases, case series, reviews, or original articles that address and shed light on one of the most controversial diagnostic fields of all time.

Dr. Gerardo Cazzato
Prof. Dr. Leonardo Resta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Dermatopathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malignant melanoma
  • dermatopathology
  • differential diagnosis
  • great mime
  • controversy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

2 pages, 184 KiB  
Editorial
Histopathological Diagnosis of Malignant Melanoma at the Dawn of 2023: Knowledge Gained and New Challenges
by Gerardo Cazzato
Dermatopathology 2023, 10(1), 91-92; https://doi.org/10.3390/dermatopathology10010013 - 13 Feb 2023
Cited by 6 | Viewed by 2638
Abstract
Year after year, the incidence and prevalence rates of cutaneous Malignant Melanoma (MM) show a continuous increase and, according to the most up-to-date American Cancer Society (ACS) projections, it is estimated that 97,610 new melanomas will be diagnosed in 2023 (about 58,120 in [...] Read more.
Year after year, the incidence and prevalence rates of cutaneous Malignant Melanoma (MM) show a continuous increase and, according to the most up-to-date American Cancer Society (ACS) projections, it is estimated that 97,610 new melanomas will be diagnosed in 2023 (about 58,120 in men and 39,490 in women) and approximately 7990 people are expected to die of melanoma (about 5420 men and 2570 women) [...] Full article

Review

Jump to: Editorial

26 pages, 714 KiB  
Review
Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature
by Chelsea Huang, Tiffany Wing-See Lau and Bruce R. Smoller
Dermatopathology 2024, 11(1), 26-51; https://doi.org/10.3390/dermatopathology11010005 - 18 Jan 2024
Viewed by 2943
Abstract
Over the past decade, molecular and genomic discoveries have experienced unprecedented growth, fundamentally reshaping our comprehension of melanocytic tumors. This review comprises three main sections. The first part gives an overview of the current genomic landscape of cutaneous melanocytic tumors. The second part [...] Read more.
Over the past decade, molecular and genomic discoveries have experienced unprecedented growth, fundamentally reshaping our comprehension of melanocytic tumors. This review comprises three main sections. The first part gives an overview of the current genomic landscape of cutaneous melanocytic tumors. The second part provides an update on the associated molecular tests and immunohistochemical stains that are helpful for diagnostic purposes. The third section briefly outlines the diverse molecular pathways now utilized for the classification of cutaneous melanomas. The primary goal of this review is to provide a succinct overview of the molecular pathways involved in melanocytic tumors and demonstrate their practical integration into the realm of diagnostic aids. As the molecular and genomic knowledge base continues to expand, this review hopes to serve as a valuable resource for healthcare professionals, offering insight into the evolving molecular landscape of cutaneous melanocytic tumors and its implications for patient care. Full article
Show Figures

Figure 1

11 pages, 1598 KiB  
Review
Balloon Cell Melanoma: Presentation of Four Cases with a Comprehensive Review of the Literature
by Gerardo Cazzato, Eliano Cascardi, Anna Colagrande, Antonietta Cimmino, Giuseppe Ingravallo, Lucia Lospalluti, Paolo Romita, Aurora Demarco, Francesca Arezzo, Vera Loizzi, Miriam Dellino, Irma Trilli, Emilio Bellitti, Paola Parente, Teresa Lettini, Caterina Foti, Gennaro Cormio, Eugenio Maiorano and Leonardo Resta
Dermatopathology 2022, 9(2), 100-110; https://doi.org/10.3390/dermatopathology9020013 - 28 Mar 2022
Cited by 6 | Viewed by 4036
Abstract
Background: balloon cell melanoma represents less than 1% of all histological forms of malignant melanoma and represents a diagnostic challenge for the dermatopathologist. Methods: in this paper we present our cases of BCM found in our daily practice from 1 January 2008 to [...] Read more.
Background: balloon cell melanoma represents less than 1% of all histological forms of malignant melanoma and represents a diagnostic challenge for the dermatopathologist. Methods: in this paper we present our cases of BCM found in our daily practice from 1 January 2008 to 31 December 2021, and we conduct a review of the literature relating to this entity in the period from the first description, 1970, to early 2022. Results: four cases of melanoma balloon cell have been extrapolated from our electronic database, while in the review of the literature we have identified 115 cases of patients with primary and/or metastatic BCM. Conclusions: we believe that future studies with numerous case series are essential not only to increase the knowledge of the pathophysiology of this neoplasm but also to correctly evaluate the response of BCM patients to new oncological therapies. Full article
Show Figures

Figure 1

Back to TopTop